Diarrhea on Wegovy (semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

At a glance

• Incidence: 29.7% in the semaglutide 2.4 mg arm vs. 16.1% placebo in STEP 1 (Wilding et al., 2021)
• Typical onset: Days 1-5 after each dose increase
• Peak timing: Days 3-5 post-escalation at most dose steps
• Usual resolution: 7-14 days after each escalation step; most patients are symptom-free by maintenance (week 68)
• First-line management: Oral hydration, low-fat/low-fiber meals, smaller portion sizes, loperamide for acute episodes if no contraindication
• Escalate if: Diarrhea persists beyond 14 days at a stable dose, signs of dehydration appear, or stool contains blood
• Discontinue if: Persistent severe diarrhea causes clinically significant dehydration, electrolyte disturbance, or acute kidney injury

Why Wegovy Causes Diarrhea: The Short Mechanism

GLP-1 receptors are expressed throughout the gastrointestinal tract. When semaglutide activates them, gastric emptying slows and small-intestinal motility changes in ways that can accelerate colonic transit in some patients, pushing stool through before water absorption is complete. A secondary contributor is the caloric and dietary shift that accompanies therapy: patients eating less fat and more liquid-consistency food alter the substrate arriving in the colon, which can shift the resident microbiome and transiently increase osmotic load. The FDA prescribing information for Wegovy lists diarrhea as one of the most common adverse reactions, consistent with the GLP-1 class effect seen across agents including liraglutide and tirzepatide.

The Dose-Escalation Schedule and Why It Matters

Novo Nordisk designed the Wegovy escalation protocol specifically to reduce GI side effects by ramping the dose gradually over 16 weeks. The schedule is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Each upward step is a new physiological challenge. Understanding that diarrhea risk resets with every escalation is the single most important thing a patient can know, because it means the pattern is predictable rather than random. The STEP 1 trial protocol used this exact 16-week ramp, and GI adverse events in the trial followed the same escalation-linked clustering.

Week-by-Week Timeline

Weeks 1-4 (0.25 mg): Low Risk, Occasional Loose Stools

The 0.25 mg starting dose is intentionally sub-therapeutic for weight loss. GI receptor activation is modest, and diarrhea at this stage is reported by a minority of patients. When it occurs, it is usually one to two loose stools in the first few days, self-resolving within 48 hours. Nauck et al. (2021) describe this starter-dose strategy across GLP-1 agents as effective at reducing early GI burden, and the STEP program data bear that out: the highest concentration of GI event discontinuations occurred at higher dose steps, not at 0.25 mg.

What to do: No pharmacological intervention needed for most patients. Drink at least 2 liters of water daily from day 1. Avoid high-fat meals on injection day and the day after.

Weeks 5-8 (0.5 mg): First Noticeable Bump

The jump from 0.25 mg to 0.5 mg is the first escalation that many patients notice in the gut. Diarrhea frequency increases modestly. Episodes typically appear within 24-72 hours of the new dose and last 2-5 days. Stool is loose rather than watery in most cases, and cramping is mild. The STEP 2 trial (Davies et al., 2021), which studied semaglutide in patients with type 2 diabetes, found that nausea and diarrhea co-occurred at this dose range and that both tended to be time-limited.

What to do: Introduce the BRAT-adjacent approach: bananas, rice, applesauce, toast, and lean protein. Reduce meal size on injection day. Over-the-counter loperamide 2 mg after the first loose stool (up to 4 mg/day) is appropriate for most adults per standard antidiarrheal guidance, though it should be avoided if there is any fever or blood in stool.

Weeks 9-12 (1.0 mg): The Most Commonly Reported Problem Window

The 0.5 mg to 1.0 mg step doubles the dose and is the escalation point associated with the highest reported diarrhea rates in clinical experience. In the STEP 1 trial, GI adverse events were most concentrated in the escalation phase rather than at maintenance, and the 1.0 mg step sits in the middle of that window. Patients at this stage may experience 3-5 loose stools per day for 4-7 days. Fatigue from fluid loss is possible. Nausea and diarrhea can occur together, which compounds the difficulty of maintaining oral intake.

The American Gastroenterological Association's 2022 clinical practice update on GLP-1 GI effects recommends that clinicians consider a dose-escalation pause (holding at the current dose for an additional 4 weeks) when GI side effects are grade 2 or higher, rather than pushing through. This pause strategy is supported in the Wegovy prescribing label.

What to do: Prioritize electrolyte replacement alongside water: oral rehydration solution (ORS) is more effective than plain water when stool losses are high. If 3 or more loose stools per day persist beyond 7 days at a stable dose, contact the prescribing clinician to discuss a dose hold. Track stool frequency with a simple log app or handwritten count so the conversation with the prescriber is data-based.

Weeks 13-16 (1.7 mg): Moderate Risk, Shorter Duration for Most

By this point, patients who have tolerated the prior escalations have some degree of physiological adaptation. GI receptor downregulation and motility accommodation appear to develop over weeks, based on pharmacodynamic data reviewed in Drucker (2018). The 1.7 mg step still triggers a diarrhea episode in a subset of patients, but the duration tends to be shorter than at 1.0 mg, roughly 3-5 days rather than 5-7, in patients who have stayed on schedule.

Patients who paused their escalation at 1.0 mg for an extra 4 weeks and then moved to 1.7 mg often report a smoother transition, consistent with the dose-hold rationale discussed in the AGA guidance cited above.

What to do: Same hydration and dietary strategy as prior steps. Watch for any signs of dehydration: dark urine, dizziness on standing, reduced urine output. These warrant same-day clinical contact.

Week 17 Onward (2.4 mg Maintenance): Settling Down

The 2.4 mg maintenance dose is the final and highest step. A meaningful proportion of patients experience a diarrhea flare in the first 1-2 weeks after this transition. However, STEP 1 long-term data show that GI adverse event rates fall substantially by weeks 20-28 compared with the escalation phase. By week 68 (the trial endpoint), diarrhea rates in the active arm had converged toward, though not fully reached, placebo levels.

The patients who continue to report diarrhea at maintenance beyond week 20 tend to fall into two groups: those with a concurrent IBS-D or functional GI diagnosis, and those who have increased dietary fat intake as appetite suppression wanes slightly. Camilleri (2021) provides a detailed review of GLP-1 colonic effects that helps explain why high-fat reintroduction can reignite symptoms.

What to do: If diarrhea persists at stable 2.4 mg beyond 4 weeks, revisit dietary fat content. A registered dietitian consultation is appropriate at this stage, both for GI symptom management and to optimize the nutritional quality of the reduced-calorie intake Wegovy supports.

Factors That Extend or Worsen the Timeline

Several variables push individual patients outside the typical timeline above:

• Concurrent metformin use: Metformin independently causes diarrhea in up to 20-30% of users per Bailey (2017). Patients on both drugs have additive GI exposure.
• High-fat diet: Fat delays gastric emptying under normal conditions, but GLP-1-mediated motility changes can override that brake effect unpredictably, leading to rapid transit events after fatty meals.
• Pre-existing IBS or IBD: These patients should be counseled before starting Wegovy that baseline GI function will make the timeline less predictable. A gastroenterology consult before initiating therapy is reasonable.
• Missed dose then restart: Missing a week and then resuming at the same dose can re-trigger an early-escalation pattern, since receptor adaptation partially reverses.

When to Call Your Prescriber Right Away

Contact your prescriber the same day if any of the following occur:

• More than 6 loose stools in 24 hours
• Blood or mucus in stool
• Diarrhea accompanied by fever above 38.5°C (101.3°F)
• Inability to keep oral fluids down for more than 12 hours
• Significant dizziness or rapid heart rate suggesting volume depletion
• Signs of acute kidney injury: markedly reduced urine output, flank pain

The FDA Wegovy label notes that severe GI events were among the reasons for discontinuation in STEP trials in approximately 1.4% of participants. That number is small, but the signal is real, and the threshold for escalating care should be low.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
• Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/34186044/
• FDA. Wegovy (semaglutide) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
• Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Nat Rev Endocrinol. 2021;17(5):255-270. https://pubmed.ncbi.nlm.nih.gov/33849657/
• American Gastroenterological Association. AGA Clinical Practice Update on the Gastrointestinal Side Effects of GLP-1 Receptor Agonists. Gastroenterology. 2022. https://pubmed.ncbi.nlm.nih.gov/35550956/
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. https://pubmed.ncbi.nlm.nih.gov/29939306/
• Camilleri M. Gastrointestinal effects of GLP-1-based therapies: mechanisms and clinical relevance. Gastroenterology. 2021;160(7):2357-2369. https://pubmed.ncbi.nlm.nih.gov/33406225/
• Bailey CJ. Metformin and the gut: the role of the gastrointestinal tract in metformin action. Diabetologia. 2017;60(9):1762-1772. https://pubmed.ncbi.nlm.nih.gov/28236332/